• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Wall Street Beat

Pulmatrix seeks to raise $5m in direct offering

January 30, 2017 By Sarah Faulkner

Pulmatrix

Pulmatrix (NSDQ:PULM) said today that it landed an agreement with several institutional investors to purchase $5.0 million of shares of common stock in a registered direct offering. The Lexington, Mass.-based company agreed to sell 2 million shares of common stock at $2.50 apiece. The offering is expected to close on Feb. 2. Pulmatrix said it […]

Filed Under: Featured, Funding Roundup, Respiratory, Wall Street Beat Tagged With: Pulmatrix Inc.

Teva wins FDA nod for inhaled asthma medications

January 30, 2017 By Sarah Faulkner

Teva Pharmaceutical

Teva Pharmaceuticals (NYSE:TEVA) said today that the FDA approved 2 inhaled asthma medications to be delivered using the company’s RespiClick breath-activated, multi-dose dry powder inhaler. The products, AirDuo RespiClick and ArmonAir RespiClick, are indicated for use in asthma patients as young as 12 years old. The Jerusalem-based company’s AirDuo RespiClick is a fixed dose combination of […]

Filed Under: Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Respiratory, Wall Street Beat Tagged With: Teva Pharmaceuticals

Novo Nordisk puts $145m into U.K. research center

January 30, 2017 By Sarah Faulkner

Novo Nordisk

(Reuters) – Novo Nordisk, the world’s top maker of diabetes drugs, is investing 115 million pounds ($145 million) in a new research center in Britain, undeterred by Brexit. The Danish company said on Monday it would invest the money over 10 years in the center based at the University of Oxford, which will employ 100 […]

Filed Under: Diabetes, Featured, Pharmaceuticals, Research & Development, Wall Street Beat Tagged With: AstraZeneca plc, GlaxoSmithKline plc, Novo Nordisk

Endo cuts staff in restructuring effort

January 26, 2017 By Sarah Faulkner

Endo Pharmaceuticals

Endo International (NSDQ:ENDP) said today that it will cut 90 full-time positions from its workforce in an effort to restructure its generics and U.S. branded pharmaceutical businesses. The company said it will invest part of the cost savings that result from its restructuring into Endo’s core products and new product development. “Last year, Endo completed […]

Filed Under: Pharmaceuticals, Wall Street Beat Tagged With: BioDelivery Sciences International, Endo Pharmaceuticals

Report: Novartis eyes sale for Alcon lens business

January 26, 2017 By Sarah Faulkner

Novartis eyes Alcon sale

Novartis (NYSE:NVS) said yesterday that it is considering selling its Alcon eye care business and will buy back up to $5 billion worth of shares over the next 12 months, in an effort to reorganize after a tough year. The company’s profits dropped -11% to $936 million in the 3 months ended Dec. 31, while sales […]

Filed Under: Featured, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Alcon, Novartis

Biogen beats Q4 earnings, misses on full-year rev forecast

January 26, 2017 By Sarah Faulkner

Biogen

Shares in Biogen (NSDQ:BIIB) rose this week after the biopharmaceutical company met expectations on Wall Street with its 4th quarter financial results, but pegged its full-year revenue forecast lower than analysts expected. The Cambridge, Mass.-based company posted profits of $649.2 million, or $2.99 per share, on sales of $2.87 billion for the 3 months ended Dec. […]

Filed Under: Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Biogen Idec

Johnson & Johnson to pay $30B for Actelion

January 26, 2017 By Sarah Faulkner

Actelion, Johnson & Johnson

After weeks of exclusive negotiations, Johnson & Johnson (NYSE:JNJ) said on Thursday that it plans to buy Swiss biotech firm Actelion (VTX:ATLN) for $30 billion in an all-cash deal. The companies have reportedly been in talks for months – Sanofi (NYSE:SNY) was also involved in discussions for Actelion, but was sidelined after J&J entered into exclusive negotiations with Actelion last […]

Filed Under: Featured, Mergers & Acquisitions, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson, Sanofi-Aventis

FDA approves 2mg Narcan nasal spray for opioid overdose treatment

January 25, 2017 By Sarah Faulkner

Adapt Pharma said today that the FDA approved the 2mg formulation of its Narcan nasal spray for the emergency treatment of opioid overdose. The 2mg dose is intended for opioid-dependent patients that are at risk for severe withdrawal, but are not at a high risk for continued opioid exposure. The approval comes 1 year after […]

Filed Under: Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Wall Street Beat Tagged With: Adapt Pharma

Trelleborg features engineered coating fabrics, contract manufacturing services for combo products

January 24, 2017 By Sarah Faulkner

Trelleborg features engineered coating fabrics, contract manufacturing services for combo products

Trelleborg plans to be on site at MD&M West 2017, a medical technology conference in California next month, highlighting its portfolio of engineered coated fabrics for medical, orthopedic and surgical applications, as well as the company’s contract manufacturing services for drug-device combination products. Trelleborg Engineered Coated Fabrics develops polyurethane, rubber and silicone-coated fabrics for devices such […]

Filed Under: Contract Services, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Trelleborg, Trelleborg Sealing Solutions

Ocular Therapeutix looks to raise $25m in public offering

January 24, 2017 By Sarah Faulkner

Ocular Therapeutix

Ocular Therapeutix (NSDQ:OCUL) said today that it launched a $25 million underwritten public offering of its common stock. The Bedford, Mass.-based company did not provide any specific pricing details for the offering. Cantor Fitzgerald & Co. is the sole bookrunner for the offering, according to regulatory filings. Yesterday, the company  said today that it resubmitted a […]

Filed Under: Featured, Funding Roundup, Optical/Ophthalmic, Wall Street Beat Tagged With: Ocular Therapeutix

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 180
  • Page 181
  • Page 182
  • Page 183
  • Page 184
  • Interim pages omitted …
  • Page 193
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS